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Androgen receptor signalling impairs docetaxel efficacy
in castration-resistant prostate cancer
Lisanne Mout1,2, Jan M. Moll2, Mingqing Chen3, Eleonora S. de Morrée1,2, Corrina M. A. de Ridder2, Alice Gibson3, Debra Stuurman2,
Ashraf Aghai2, Sigrun Erkens-Schulze2, Ron H. J. Mathijssen1, Alex Sparreboom 3, Ronald de Wit1, Martijn P. Lolkema 1 and
Wytske M. van Weerden 2
Androgen receptor (AR) signalling drives neoplastic growth and therapy resistance in prostate cancer. Recent clinical data show
that docetaxel combined with androgen deprivation therapy improves outcome in hormone-sensitive disease. We studied whether
testosterone and AR signalling interferes with docetaxel treatment efficacy in castration-resistant prostate cancer (CRPC). We found
that testosterone supplementation significantly impaired docetaxel tumour accumulation in a CRPC model, resulting in decreased
tubulin stabilisation and antitumour activity. Furthermore, testosterone competed with docetaxel for uptake by the drug
transporter OATP1B3. Irrespective of docetaxel-induced tubulin stabilisation, AR signalling by testosterone counteracted docetaxel
efficacy. AR-pathway activation could also reverse long-term tumour regression by docetaxel treatment in vivo. These results
indicate that to optimise docetaxel efficacy, androgen levels and AR signalling need to be suppressed. This study lends evidence for
continued maximum suppression of AR signalling by combining targeted therapeutics with docetaxel in CRPC.
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BACKGROUND
The treatment of advanced or metastatic prostate cancer (PCa) is
focussed around androgen deprivation therapy (ADT), as testoster-
one and dihydrotestosterone promote neoplastic behaviour of PCa
cells through androgen receptor (AR) signalling. While ADT almost
invariably induces disease regression, the majority of prostate
tumours will at some point become resistant due to AR-pathway
aberrations.1–3 For patients who progress while receiving ADT, also
referred to castration-resistant prostate cancer (CRPC), docetaxel is
the standard first-line chemotherapy. Recently, the combination of
ADT with docetaxel has also been introduced in the metastatic
castrate-naive setting as this combination significantly increased
overall survival.4,5 Conversely, docetaxel without ADT after radical
prostatectomy did not delay disease recurrence.6 These clinical trials
suggest that the antitumour efficacy of docetaxel in castrate-naive
PCa (CNPC) is improved by inhibition of AR-pathway signalling. In
this study, we explore the impact of sustained androgen levels and/
or AR-pathway signalling on docetaxel efficacy in CRPC. Moreover,
we studied the underlying mechanisms of AR-pathway activation on
docetaxel treatment efficacy by examining docetaxel tumour
accumulation, target engagement and cell death induction.
METHODS
The AR-positive CRPC patient-derived cell line models, PC346C-DCC-
K and VCaP-DCC-E, were derived from the hormone-sensitive
prostate cancer cell lines, PC346C and VCaP, respectively, through
long-term propagation in castrate conditions.7 Both PC346C-DCC-K
and the parental cell line PC346C do not express AR variants
(Supplementary Fig. 1),8 while VCaP-DCC-E shows increased
expression of AR-V7 compared to VCaP. Furthermore, these cell
lines do not express ABCB1 (P-glycoprotein), which has been shown
to induce multidrug resistance.9 For in vivo experiments, NMRI nu/
nu male mice were subcutaneously inoculated with PC346C-DCC-K
cells and surgically castrated once tumours established (Supple-
mentary Methods). After 1 week, mice received a testosterone pellet
or treatment control. One injection of docetaxel (33mg/kg) or NaCl
was given the following day. Tumour volume was monitored weekly
by callipers and mice were euthanised before the humane endpoint
was reached by cervical dislocation (details in Supplementary
Methods).10 For in vivo accumulation studies, tumours were
obtained 3 days after docetaxel treatment. Tumour samples were
used to determine docetaxel accumulation by liquid chromatogra-
phy with tandem mass spectrometry,11,12 α-tubulin acetylation by
western blot and cell death by terminal deoxynucleotidyl transferase
dUTP nick-end labeling (TUNEL) staining. Uptake of docetaxel by
OATP1B3 was studied in Hek293T cells transiently expressing
SLCO1B3, uptake of C14-docetaxel was measured in the presence
or absence of testosterone. To assess the impact of AR-pathway
stimulation on docetaxel sensitivity, cell viability assays were
conducted. We exposed PC346C-DCC-K and VCaP-DCC-E cells
in vitro to a dose range of docetaxel with or without androgens.
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RESULTS
We first investigated the effect of androgen signalling on the
antitumour efficacy of docetaxel in the AR-positive CRPC model
PC346C-DCC-K (Supplementary Fig. 1). In all castrate mice,
docetaxel treatment resulted in long-term and complete tumour
regression (Fig. 1a). While in testosterone-supplemented mice,
docetaxel treatment only induced a short-term tumour response,
after which all tumours rapidly progressed. The partial response to
docetaxel in these mice shows that testosterone interfered with
docetaxel treatment efficacy. We therefore examined docetaxel
tumour accumulation in the presence of testosterone, as we
previously identified that impaired uptake of taxane chemother-
apeutics correlates with treatment resistance.11 Indeed,
testosterone-supplemented mice displayed a 40% reduction of
docetaxel tumour levels: median of 2.8 ng/mg tumour from
testosterone-supplemented mice versus 4.4 ng/mg in androgen-
deprived animals (P value < 0.001; Fig. 1b). Moreover, testosterone
supplementation resulted in strong AR-pathway activation in
PC346C-DCC-K tumours as exemplified by increased prostate-
specific antigen production, AR nuclear localisation, AR target
gene expression and tumour cell proliferation (Supplementary
Fig. 2). To study the underlying mechanism of impaired docetaxel
tumour accumulation, we examined the impact of testosterone on
docetaxel uptake by the influx drug transporter OATP1B3
(encoded by SLCO1B3). SLCO1B3 is frequently overexpressed in
prostate cancer, and docetaxel and testosterone are both
OATP1B3 substrates13–16 (Supplementary Fig. 3). We found that
in Hek293T cells expressing SLCO1B3, pre/coincubation with
testosterone, decreased docetaxel uptake by 17% (P value=
0.004; Fig. 1c). This implicates that testosterone competes with
docetaxel for OATP1B3-mediated uptake, resulting in reduced
docetaxel tumour accumulation. As testosterone supplementation
interferes with docetaxel accumulation, this will likely affect
tubulin target engagement and subsequent stabilisation. We
therefore investigated acetylation of α-tubulin, which is a result of
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Fig. 1 Testosterone supplementation strongly impairs docetaxel efficacy and accumulation. a Impact of testosterone supplementation on
docetaxel treatment in tumour bearing mice (PC346C-DCC-K). Kaplan–Meier curve depicting the cumulative survival in the four treatment
groups; Docetaxel (once 33mg/kg i.v.) or placebo in castrate (DocCx n= 13 and PlacCx n= 13, respectively) or testosterone-supplemented
mice (PlacTest n= 6 and DocTest n= 6, respectively). Time till progression was calculated from the day of docetaxel treatment until tumours
exceeded a volume of 1500mm3. Mice were censored when tumours did not reach 1500mm3 in size during the maximum follow-up of
60 days. One mouse in the DocCx treatment group was euthanised due to continued weight loss after treatment. Results from the pair-wise
comparison using the log-rank test are shown in the table. b Docetaxel accumulation in PC346C-DCC-K tumours obtained 3 days after
treatment in castrate or testosterone-supplemented mice (DocCx n= 6 and DocTest n= 6, respectively). ***P < 0.0001. c Normalised uptake of
3H-estradiol-17β-D-glucuronide (EbG) and C14-docetaxel in Hek293T cells transiently expressing SLCO1B3, pre/coincubated with 200 µM
testosterone or vehicle control. Uptake of EbG and docetaxel was normalised to uptake in SLCO1B3-expressing cells in the absence of
testosterone, and EbG was used as a positive control for OATP1B3-mediated uptake. Shown are the individual normalised uptake values (n=
9) obtained from three experiments. **P < 0.01 and *P < 0.05, respectively.
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Fig. 2 Testosterone and AR-pathway activity interfere with docetaxel-induced target engagement and cell death. a Acetylated-α-tubulin
as a measurement for tubulin stabilisation in PC346C-DCC-K tumours obtained 3 days after docetaxel treatment, in castrate and testosterone-
supplemented mice (DocCx n= 6 and DocTest n= 6, respectively). Acetylated-α-tubulin signal intensity was obtained by immunoblotting
individual tumour samples and normalised to GAPDH loading control. Statistical comparison was performed by a two-sided T test. b
Quantification of TUNEL stainings in short-term docetaxel-treated PC346C-DCC-K tumours from castrate and testosterone-supplemented mice
(DocCx n= 6 and DocTest n= 6, respectively). TUNEL signal was compared to three tumours obtained from castrate mice (Cx) with no/low
docetaxel accumulation (≤0.1 ng/mg tumour) after short-term treatment. Fraction of TUNEL-positive pixels was normalised to Hoechst signal,
and data plotted is the median TUNEL-positive pixels of the individual tumour samples. ***P < 0.001 and *P < 0.05. n.s. Not significant. c Impact
of androgen supplementation (R1881; orange data points) on docetaxel response as compared to androgen-deprived culture conditions
(DCC; blue data points). Docetaxel sensitivity was assessed in the AR-positive CRPC cell lines PC346C-DCC-K (top panel) and VCaP-DCC-E
(lower panel) (both n= 3). Docetaxel response was normalised to cell density at the start of docetaxel treatment (dashed line) and plotted as
relative cell expansion. Data were fitted using a non-linear curve fit to compare the two culture conditions; P values are displayed. d Individual
tumour growth curves of docetaxel-treated PC346C-DCC-K tumours under castrate conditions (from day 0, n= 7). Sixty days after docetaxel
treatment, mice were supplemented with a testosterone implant (red data points) and tumour growth was monitored until tumours exceeded
1000mm3, or a maximum follow-up of 21 days.
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acetylation was significantly correlated with docetaxel tumour
accumulation levels (Supplementary Fig. 4a, b). Moreover, we
observed a trend towards decreased tubulin stabilisation in
PC346C-DCC-K tumours from short-term docetaxel-treated mice
supplemented with testosterone (19% decrease, P= 0.17; Fig. 2a
and Supplementary Fig. 4c). Overall, these data confirm that
testosterone reduces docetaxel target engagement as a result of
impaired tumour accumulation. To further assess docetaxel
activity, we quantified docetaxel-induced cell death by TUNEL.
Testosterone interfered with docetaxel-induced cell death, as
shown by the strong reduction in TUNEL staining compared to
docetaxel-treated castrate mice (P ≤ 0.001; Fig. 2b and Supple-
mentary Fig. 5). Moreover, TUNEL staining in tumours from
docetaxel-treated mice supplemented with testosterone was not
significantly different to untreated controls (P value= 0.36).
Therefore, tubulin stabilisation by docetaxel treatment in
testosterone-supplemented mice, albeit reduced, did not translate
into cell death induction. We thus hypothesised that AR-pathway
activation by testosterone further abrogates docetaxel efficacy.
Indeed, a small but consistent survival advantage was achieved by
R1881 under effective docetaxel concentrations in AR-positive
CRPC cell lines (Fig. 2c; > 0.3 nM docetaxel with P= 0.032 and
0.073 for PC36C-DCC-K and VCaP-DCC-E, respectively). R1881 did
not impact docetaxel response in AR-negative prostate cancer
(PCa) cells (Supplementary Fig. 6). This indicates that androgen
stimulation can protect AR-positive CRPC cells from docetaxel-
induced cell death. The increased cell viability under docetaxel
treatment led us to investigate whether AR-pathway stimulation
alone could re-induce proliferation in vivo. We therefore repeated
the docetaxel treatment in castrate mice as depicted in Fig. 1a and
investigated the impact of AR-pathway activation. Testosterone-
induced strong AR-pathway stimulation, as shown by AR nuclear
localisation and target gene expression, which led to rapid
outgrowth in five out of seven PC346C-DCC-K tumours (Fig. 2d
and Supplementary Fig. 7). Overall, AR-pathway activation was
able to overcome long-term tumour regression induced by
docetaxel treatment.
DISCUSSION
In this study, we investigated the impact of testosterone and AR-
pathway stimulation on the antitumour efficacy of docetaxel in
CRPC xenografts and cell lines. Testosterone impaired docetaxel
antitumour activity through two different modes of action:
interference with docetaxel tumour accumulation, thereby redu-
cing tubulin stabilisation and AR-pathway activation protecting
cells from docetaxel-induced cell death (Fig. 1b). Reduced levels of
docetaxel tumour accumulating by testosterone are, at least
partially, mediated through competition for OATP1B3 uptake
(Fig. 1c). OATP1B3 is an influx transporter of particular interest,
because it is frequently overexpressed in CNPC and metastatic
CRPC (mCRPC) compared to normal adjacent prostate.18–20
Moreover, OATP1B3 seems to have a dual character in PCa, while
SLCO1B3 overexpression has been linked to testosterone uptake;
downregulation was correlated with docetaxel resistance
in vivo.13,21 We previously showed that cabazitaxel efficacy and
tumour accumulation are also impaired by testosterone, indicating
that testosterone impacts taxane efficacy in general.8
The current study explored the impact of reduced taxane tumour
accumulation on tubulin target engagement. The absence of
acetylated α-tubulin has previously been described as a biomarker
of paclitaxel resistance and was restored upon re-sensitisation.17
Here, we found that docetaxel accumulation strongly correlated
with acetylated α-tubulin signal in short-term docetaxel-treated
tumours. Moreover, tubulin acetylation tended to be decreased in
mice receiving docetaxel together with testosterone (Fig. 2a).
Although CRPC xenografts from testosterone-supplemented doc-
etaxel-treated mice still displayed substantial tubulin stabilisation,
this did not translate into increased cell death induction (Fig. 2b).
These results led us to conclude that testosterone activation of the
AR pathway compromised the antitumour activity of docetaxel. This
was in part demonstrated by the impact of R1881 supplementation
on docetaxel sensitivity in vitro in two AR-expressing CRPC cell lines.
Of note, the VCaP-DCC-E cell line is positive for AR-V7, while PC346C-
DCC-K does not express AR variants (Supplementary Fig. 1),8 this
implicates that regardless of variant expression, AR-pathway activity
interferes with taxane efficacy. In addition, AR-pathway activation by
testosterone stimulated regrowth of docetaxel-treated dormant
tumours (Fig. 2d). Recent clinical findings, albeit retrospective
analyses, also suggest an interaction between taxane efficacy and
testosterone. These studies showed that CRPC patients with
suboptimal testosterone serum levels had significantly shorter
progression-free survival following docetaxel treatment.22,23
Our data strongly suggest that taxane efficacy can be optimised
by maintaining suppression of testosterone levels in order to
minimise interference with docetaxel tumour accumulation and
block AR-driven prosurvival signalling. Several phase II/III trials are
currently combining (novel) AR-targeted therapies with taxanes in
mCRPC.24 Our findings lend support to the potential benefit of
combining docetaxel with additional blocking of AR signalling
in mCRPC.
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